Sign in
Taking people in United StatesNo phase

Using immune cell testing to guide cytomegalovirus prevention after lung transplant

Follows immune response to cytomegalovirus in adults who received a lung transplant.

Key facts

Who runs it
University of Miami
Where
Miami, United StatesSee the site
Trial code
Registry title
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
Status
Recruiting
People taking part
100 people, planned
Started
3 Jul 2024
Expected to end
30 Dec 2026
Type of study
Observational
Record updated
23 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults waiting for a lung transplant who have had past CMV infection, shown by a blood test. The trial follows their immune response to CMV (cytomegalovirus) for 1 year.

Age
18 Years to 75 Years
Sex
All sexes can join.
Disease stage
People expected to receive a lung transplant, either double lung or single lung.
Biomarker or test result
Positive CMV IgG blood test before the transplant (a sign of past CMV infection).

Main reasons for not taking part

  • Negative CMV IgG before the transplant
  • Pregnant or breastfeeding women
  • People with HIV infection
  • People waiting for a combined organ transplant, such as lung-heart or lung-kidney

This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Anticipated to receive a lung transplant (both double lung and single lung)

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult patients over 18 years of age
  • Lung transplant candidates with positive CMV IgG
  • Anticipated to receive a lung transplant (both double lung and single lung)

Who cannot take part

  • Negative CMV IgG prior transplant
  • HIV infected patients
  • Combined organ (e.g., lung-heart, lung-kidney) transplant candidates
  • Pregnant or breastfeeding women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • University of MiamiMiami, United StatesContact: Yoichiro Natori, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.

The group in the trial

  • Prophylaxis guided by Cytomegalovirus-specific T cell Immunity

    The immunological response of participants in this group will be followed for 1 year.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients: a Single Center Prospective Study
Plain-language title
Using immune cell testing to guide cytomegalovirus prevention after lung transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06494033, who can take part
Record updated
23 March 2026